Isovitexin

Isovitexin is a C-glycosylflavone (apigenin-6-C-glucoside) found in plants such as passion flower, pearl millet, and bamboo leaves. Its primary mechanisms include inhibition of the steroidogenic enzyme CYP17A1, suppression of pro-inflammatory cytokines, and induction of apoptosis in cancer cell lines.

Origin & History

Isovitexin is a naturally occurring C-glycosyl flavonoid found in various medicinal plants like those in the Vitex genus and Ginkgo biloba. It is typically extracted from plant materials such as Chimonanthus leaves using solvent extraction or isolation from crude leaf extracts.

Historical & Cultural Context

Isovitexin occurs in plants like Ginkgo biloba and Vitex species, which are used in traditional Chinese medicine for inflammation. However, specific traditional uses of isovitexin alone are not documented.

Health Benefits

• Induces apoptosis in MCF-7 breast cancer cells at <10 nM through CYP17A1 inhibition (in vitro study).[1]
• Reduces inflammation and cytokine levels in GA-induced contact dermatitis mouse models, showing more effectiveness than dexamethasone in some measures (animal study).[2]
• Exhibits protective effects against DSS-induced colitis in mice by inhibiting specific inflammatory pathways (animal study).[10]
• Targets β-cell protection and insulin signaling in preclinical diabetes models (in vitro study).[3]
• Modulates NF-κB pathway and reduces T-cell proliferation in inflammatory models (animal study).[2]

How It Works

Isovitexin inhibits CYP17A1 (17α-hydroxylase/17,20-lyase), a cytochrome P450 enzyme critical in androgen and estrogen biosynthesis, triggering apoptosis in hormone-sensitive cancer cells at concentrations below 10 nM. It suppresses NF-κB signaling and reduces downstream pro-inflammatory mediators including TNF-α, IL-6, and IL-1β, accounting for its anti-inflammatory effects observed in contact dermatitis models. Additionally, isovitexin activates the Nrf2/HO-1 antioxidant pathway and modulates MAPK cascades, contributing to its reported cytoprotective and neuroprotective actions.

Scientific Research

No human clinical trials or meta-analyses on isovitexin were identified. Evidence is limited to preclinical in vitro, in vivo animal, and computational studies, indicating preliminary findings without standardized human data.

Clinical Summary

Current evidence for isovitexin is predominantly preclinical, derived from in vitro cell studies and rodent models, with no published randomized controlled trials in humans. In vitro data show induction of apoptosis in MCF-7 breast cancer cells at sub-10 nM concentrations via CYP17A1 inhibition. Animal studies using gallic acid-induced contact dermatitis mouse models demonstrate reductions in inflammatory cytokines that exceeded the efficacy of dexamethasone on certain measures, though direct translation to human outcomes remains unestablished. The absence of human pharmacokinetic and clinical efficacy data means definitive dosing recommendations and therapeutic claims cannot yet be made.

Nutritional Profile

Isovitexin (apigenin-6-C-glucoside) is a C-glycosyl flavonoid with molecular formula C₂₁H₂₀O₁₀ (MW ~432.38 g/mol). It is not a macronutrient source but a bioactive polyphenolic compound found naturally in mung bean (Vigna radiata) seed coats (~0.5–2 mg/g dry weight), passion fruit (Passiflora incarnata) leaves (~1–5 mg/g), bamboo leaves (~0.3–1.5 mg/g), hawthorn (Crataegus spp.) fruit, and rice hull extracts. As a C-glycoside, isovitexin is more resistant to hydrolysis in the GI tract compared to O-glycosides, resulting in slower but more sustained absorption; oral bioavailability is estimated to be low-to-moderate (~5–15%), improved modestly by co-administration with lipids or piperine. It possesses documented antioxidant (ORAC and DPPH scavenging), anti-inflammatory (NF-κB and MAPK pathway inhibition), and pro-apoptotic activities. Typical research dosages in animal models range from 10–100 mg/kg body weight. No significant vitamin or mineral content as an isolated compound.

Preparation & Dosage

No clinically studied dosages in humans are available. Preclinical studies used concentrations up to 100 μM in vitro and dose-dependent administrations in vivo without standardized mg/kg. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Isovitexin pairs well with (1) **Vitexin** (apigenin-8-C-glucoside), its positional isomer, as the two co-occur naturally in Passiflora and bamboo leaf extracts and show additive antioxidant and anti-inflammatory effects via complementary ROS-scavenging mechanisms; (2) **Piperine** (5–10 mg), which inhibits hepatic glucuronidation and intestinal P-glycoprotein efflux, thereby significantly enhancing isovitexin's oral bioavailability; (3) **Curcumin** (200–500 mg), which synergistically suppresses NF-κB signaling—curcumin targets IKKβ while isovitexin inhibits upstream MAPK/ERK phosphorylation, producing a more complete blockade of pro-inflammatory cytokine cascades (TNF-α, IL-6, IL-1β); (4) **EGCG (epigallocatechin gallate)** (100–200 mg from green tea), which complements isovitexin's CYP17A1 inhibition with its own aromatase (CYP19) inhibitory activity, potentially offering a broader anti-proliferative profile in hormone-sensitive cancers; and (5) **Quercetin** (250–500 mg), which shares overlapping but non-identical antioxidant pathways (Nrf2/ARE activation) and can stabilize isovitexin against oxidative degradation in formulation.

Safety & Interactions

No human clinical safety trials for isovitexin have been published, making a comprehensive adverse effect profile unavailable at this time. Because isovitexin inhibits CYP17A1, it may theoretically interact with hormonal therapies, corticosteroids, or other drugs metabolized via cytochrome P450 enzymes, warranting caution in those populations. Its anti-inflammatory activity may additively or synergistically interact with NSAIDs, immunosuppressants, or corticosteroids, potentially altering their efficacy or increasing side effect risk. Pregnant or breastfeeding individuals and those with hormone-sensitive conditions should avoid supplementation until human safety data are available.